{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-060210","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.795201+00:00","generated_at":"2026-06-08T17:04:11.229150+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioAtla Q3 net loss $33.3M; FDA backs registrational path for BA3011 in NSCLC","bullets":["Net loss widened to $33.3M in Q3 2023 from $25.8M a year ago, driven by a 43% rise in R&D costs.","Cash fell to $141.3M at Sep 30, down from $215.5M at Dec 31 2022; now expected to fund operations into 2H 2025.","FDA supportive of registrational path for CAB-AXL-ADC (BA3011) in NSCLC; detailed Phase 2 data to be presented in early December.","New partial responses observed with CAB-ROR2-ADC (BA3021) in melanoma and head & neck cancer at Phase 2.","Phase 2 for CAB-CTLA-4 (BA3071) initiated with first patient in; Phase 1 data and R&D Day on Dec 13."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-060210","json":"https://secwatch.observer/filing/0000950170-23-060210.json","markdown":"https://secwatch.observer/filing/0000950170-23-060210.md","text":"https://secwatch.observer/filing/0000950170-23-060210.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000095017023060210/0000950170-23-060210-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000095017023060210/bcab-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T17:04:11.229150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"38060fe5393be3d55860c8f74954dda2741aecc8","claim":"BioAtla, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 7, 2023, BioAtla, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826892/000095017023060210/0000950170-23-060210-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}